chronic kidney disease

Ardelyx (ARDX.Q) announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for…
GlaxoSmithKline (GSK.NYSE) today announced positive headline results from five studies of the Phase 3 ASCEND program, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor…